GOG-0265 Study in Metastatic Cervical Cancer Selected for Late-Breaking Data Presentation at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer
30 janv. 2017 08h30 HE
|
Advaxis
PRINCETON, N.J., Jan. 30, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that an abstract on data...
New Published Research Reveals that Cervical Cancer Mortality Rates May Be Significantly Higher in the United States than Previously Reported
25 janv. 2017 08h00 HE
|
Advaxis
PRINCETON, N.J., Jan. 25, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today pointed to research published in the...
Advaxis Provides 2017 Business Outlook
09 janv. 2017 08h00 HE
|
Advaxis
PRINCETON, N.J., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today issued its 2017 business outlook to...
Discussion on Advaxis’ ADXS-NEO, ADXS-HOT Programs Held During the International Congress on Immunotherapies in Cancer
12 déc. 2016 08h15 HE
|
Advaxis
Presentation detailed Advaxis’ bacterial vector system, new preclinical program in hotspots PRINCETON, N.J., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage...
Advaxis to Present Data at ImVacS-Immunization and Vaccine Summit on Use of Detoxified Listeriolysin O (dtLLO) as an Effective Adjuvant in Vaccine Formulations
07 déc. 2016 08h00 HE
|
Advaxis
PRINCETON, N.J., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that preclinical data on the...
Advaxis to Present at the Jefferies 2016 London Healthcare Conference
15 nov. 2016 08h00 HE
|
Advaxis
PRINCETON, N.J., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Daniel O’Connor,...
Advaxis to Present Phase 1 Combination Data and New Preclinical Data Using AXAL at Upcoming Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting
11 nov. 2016 07h30 HE
|
Advaxis
Phase 1 AXAL and durvalumab combination trial shows safety and tolerability in cervical and HPV+ head and neck cancerPreclinical data demonstrate synergistic antitumor effects of AXAL combined with a...
Advaxis Announces GOG-0265 12-month Overall Survival Rate of 37.5% in Stage 2
24 oct. 2016 08h00 HE
|
Advaxis
Data in 50 patients with recurrent metastatic carcinoma of the cervix demonstrates a 52% increase in 12-month overall survival rate PRINCETON, N.J., Oct. 24, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc....
Advaxis Initiates Combination Portion of Phase 1/2 Study with Merck
20 oct. 2016 07h30 HE
|
Advaxis
KEYNOTE-046 study to evaluate KEYTRUDA® in combination with ADXS-PSA Advaxis begins screening patients for Phase 3 AIM2CERV study in cervical cancer PRINCETON, N.J., Oct. 20, 2016 (GLOBE...
Advaxis to Receive $2.5M through the New Jersey Economic Development Authority NOL Program
13 oct. 2016 08h00 HE
|
Advaxis
PRINCETON, N.J., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, has received preliminary approval for a $2.7...